ICER updates cost-effectiveness threshold for bluebird, Vertex and CRISPR's dueling sickle cell gene therapies
Fierce Pharma
JULY 14, 2023
But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned. . | The potentially curative promise of gene therapies often carries a steep price tag.
246 
Let's personalize your content